http://www.ama-assn.org/resources/doc/usan/vercirnon.pdf
|
vercirnon
|
|
| Trade Name: | Traficet-EN |
| Synonym: | CCX282-B, GSK1605786, GSK 1605786 |
- C22H21ClN2O4S
- Average mass: 444.931091
4-(2-(4-(tert-butyl)phenylsulfonamido)-5-chlorobenzoyl)pyridine 1-oxide
698394-73-9 [RN]
Anti-inflammatory intended to treat Crohn’s
disease and inflammatory bowel disease
GSK1605786A (formerly CCX282-B) targets chemokine receptor CCR9, which is expressed selectively on intestinal lymphocytes and dendritic cells. CCR9 mediates migration of immune cells to the intestine, and blockade of the receptor inhibits migration.
GSK1605786A is being studied in CD at a dose of 500 mg by mouth once daily or 500 mg by mouth twice daily versus placebo. Final data is anticipated to be collected mid-2012 for a study evaluating efficacy over a 12-week treatment period.
A study reviewing maintenance of remission is expected to be complete in July 2014 and a long-term safety study is scheduled for completion in July 2015.
GSK-1605786 (CCX-282; Traficet-EN), a selective antagonist of the CC chemokine receptor (CCR9), is being developed by GlaxoSmithKline plc under license from ChemoCentryx Inc for the potential treatment of inflammatory bowel disease, including Crohn’s disease and celiac disease. CCR9 is a tissue-specific lymphocyte trafficking molecule that selectively attracts both B- and T-cells to the small gut. Inhibition of CCR9 by GSK-1605786 may inhibit B- and T-cell entry to the small gut and ameliorate inflammation while leaving immune function at other anatomical sites unaffected. GSK-1605786 was assessed as a treatment for moderate-to-severe Crohn’s disease in the phase II/III PROTECT-1 trial and as a treatment for celiac disease in a phase II trial. Data suggest that GSK-1605786 is efficacious in patients with Crohn’s disease with the advantage of being orally bioavailable.

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike